INVESTMENTS TO ADDRESS HEALTH INEQUITIES IN PROSTATE CANCER CARE Movember funds three Australian programs targeting under-served populations
SEGMENT
Filmed in Melbourne | February 2025
INTERVIEWS
Sarah Weller
Global Director – Prostate Cancer, Movember
Kris Bennett,
Director – Prostate Cancer Health Equity, Movember
Movember is committed to advancing new research, cutting-edge treatments, and healthy behaviours, and advocating for inclusive, gender-responsive healthcare that caters to the unique needs of men, women, and gender-diverse individuals from diverse cultural backgrounds. In doing so, they hope to forge a future where barriers to healthy living are overcome, stigmas are removed, and where everyone has an equal opportunity to live a long, healthy life.
Income, education, geographical location, and discrimination based on ethnicity, race, gender and sexual orientation, are only a fraction of factors that can negatively affect a person’s quality of cancer care. This is defined as the “equity gap” and it’s costing people their lives.
Timed to coincide with World Cancer Day 4th February 2025, Movember announced prostate cancer investment of $5.5 million. Eighteen grants (16 proposals and 2 community development grants) are slated to directly tackle inequities in prostate cancer care. The funding will be over three years with the grants spread across five countries – six in Canada, five in the United Kingdom, three in Australia, three in the United States and one in Ireland – each having a specific focus population and care area.
AUSTRALIAN FUNDING FOR TARGETED PROSTATE CANCER CARE OUTREACH PROGRAMS
– The prostate cancer mortality rate in remote areas is almost 20% higher than in major cities. Access to treatment is the leading cause. This equity gap is what the Royal Flying Doctor Service of Australia’s grant will address, to improve access to and use of prostate cancer treatment services in rural and remote areas.
– Currently, prostate cancer data on the culturally and linguistically diverse communities of South Western Sydney is insufficient. That’s the first roadblock to improving this historically overlooked group’s prostate cancer care. The George Institute for Global Health aims to fill in the blanks with population level data to help close this equity gap.
– Australian Prostate Centre will create culturally appropriate prostate cancer services and practices for the LGBTQIA+ community, to counter the fear of discrimination and stigma that often stands in its way of getting prostate cancer screenings and diagnoses.
Australian Health Journal spoke with Movember about these targeted outreach programs in Australia and the hope they will help provide education and empower historically and intentionally excluded communities, using community stakeholders and voices to build trust. Collaborations with healthcare providers, academic institutions, and community-based organisations will share resources and expertise to develop tailored solutions.
-
The role of genomic screening in transforming public health
Dr Jane Tiller is a lawyer, genetic counsellor and public health researcher. She is Ethical, Legal & Social Adviser in Public Health Genomics at Monash University, and a National Health and Medical Research Council Investigator Grant holder. Jane is passionate about the use of genomics to prevent disease, and in delivering equitable access to preventive genetic information at the population level. She is co-lead of DNA Screen, a world-first study piloting the offer of preventive DNA screening to the Australian adult population. DNA Screen has tested over 10,000 young people for genetic high risk of medically actionable conditions such as cancer and heart disease, finding about 2% of participants had genetic high risk. Jane is leading efforts to secure Commonwealth Government funding to expand the DNA Screen program, with the eventual goal of the development of a public health population screening program for disease prevention based on high genetic risk.
-
Maximising benefits, minimising harms in population health screening
Population screening is an important contributor to advancing health outcomes through the early detection of and successful intervention for chronic disease. The evolution of science, technology and evidence relating to diseases which are or may be amenable to a population screening approach deserve broad discussion and the sharing of expertise and evidence. They also warrant close scrutiny in context of health policy and health resource allocation considerations.
In March, Public Health Association of Australia (PHAA) convened Screening Conference Conference 2025 with the theme of ‘Population Screening for Chronic Disease – Maximising Benefits, Minimising Harms’.
-
Targeted National Lung Cancer Screening Program commences in 2025
In February 2025, Australian Health Journal spoke with Mark Brooke, Chief Executive Officer of Lung Foundation Australia, at the 10th Australian Lung Cancer Conference in Adelaide, on the upcoming commencement of the National Lung Cancer Screening Program (NLCSP)
